Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Adaptive Randomized Neoadjuvant Two Arm Trial in Triple-negative Breast Cancer Comparing a Mono Atezolizumab Window Followed by a Atezolizumab - CTX Therapy with Atezolizumab - CTX Therapy (neoMono)

Next Previous
Search
Trial Profile

An Adaptive Randomized Neoadjuvant Two Arm Trial in Triple-negative Breast Cancer Comparing a Mono Atezolizumab Window Followed by a Atezolizumab - CTX Therapy with Atezolizumab - CTX Therapy (neoMono)

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 18 Mar 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Atezolizumab (Primary) ; Carboplatin (Primary) ; Cyclophosphamide (Primary) ; Epirubicin (Primary) ; Paclitaxel (Primary)
  • Indications Early breast cancer; Male breast cancer; Triple negative breast cancer
  • Focus Proof of concept; Therapeutic Use
  • Acronyms neoMono

    • Most Recent Events

    • 04 Nov 2024 Status changed from active, no longer recruiting to completed.
    • 08 Jan 2024 Planned End Date changed from 1 Jan 2026 to 31 Aug 2024.
    • 09 Dec 2023 Results of primary endpoint analysis presented at the 46th Annual San Antonio Breast Cancer Symposium

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top